NCT00709163 - Nesiritide - Dilated Cardiomyopathy | Biotech Hunter

Enrollment

20

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions

Dilated Cardiomyopathy

Interventions

DRUG

Nesiritide

The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.

DRUG

5% Dextrose

The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.

Trial Locations (1)

90095

Mattel Children's Hospital at UCLA, Los Angeles